Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9942722 | 0.81 | APP (0.53) | FFAR1AOC3CA1CA2CA12 | |
| SCHEMBL1420018 | 0.78 | ALDH1A1 (0.42) | FFAR1AOC3CA1CA2CA12 | |
| SCHEMBL28924125 | 0.78 | ALDH1A1 (0.42) | FFAR1AOC3CA1CA2CA12 | |
| SCHEMBL8943724 | 0.78 | CA1 (0.47) | FFAR1AOC3CA1CA2CA12 | |
| SCHEMBL5323387 | 0.78 | TSHR (0.54) | AOC3CA1CA2CA12CA7 | |
| SCHEMBL9185138 | 0.78 | TSHR (0.54) | AOC3CA1CA2CA12CA7 | |
| SCHEMBL6168264 | 0.78 | CA1 (0.46) | AOC3CA1CA2CA12CA7 | |
| SCHEMBL1200448 | 0.78 | TSHR (0.54) | AOC3CA1CA2CA12CA7 | |
| SCHEMBL2683955 | 0.77 | KMT2A (0.47) | MAPK1ALDH1A1TSHRL3MBTL1ACP3 | |
| SCHEMBL22122696 | 0.77 | KMT2A (0.47) | MAPK1ALDH1A1TSHRL3MBTL1ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156794-B | Tricyclic fused triazole compound and preparation method and application thereof | 天津理工大学 | 2021-11-09 | — | — | CN | disclosed |
| US-20040181094-A1 | Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181094-A1 | Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants | POLR1G, PYM1, APEX1 | FFAR1 4767/4885AOC3 26/4885CA1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.